StockNews.AI
NKTR
StockNews.AI
167 days

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

1. Nektar Therapeutics to announce Q4 2024 results on March 12, 2025. 2. CEO Howard Robin will present during the earnings call. 3. Nektar is developing immunological treatments for autoimmune diseases. 4. Lead candidate Rezpegaldesleukin is in Phase 2b trials for dermatitis and alopecia. 5. Ongoing trials evaluate NKTR-255 for cancer treatment in partnership with collaborators.

Earnings
+0.38%Current Return
VS
-1.78%S&P 500
$0.857903/05 06:04 PM EDTEvent Start
$0.861203/07 12:37 AM EDTLatest Updated
5m saved
Insight
Article

FAQ

Why Bullish?

Nektar's advancements in clinical trials may attract investor interest, boosting stock price.

How important is it?

The announcement of upcoming financial results can impact investor perceptions and stock volatility.

Why Long Term?

Successful trial results might enhance market position and revenues over time.

Related Companies

AMGNMRNANVTA
, /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the fourth quarter and year-ended December 31, 2024 on Wednesday, March 12, 2025, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. This press release and live audio-only webcast of the conference call can be accessed through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com/. The web broadcast of the conference call will be available for replay through April 12, 2025. To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in San Francisco, California. For further information, visit www.nektar.com and follow Nektar on LinkedIn. Contacts: For Investors:Vivian Wu of Nektar Therapeutics(628) 895-0661 For Media:Madelin HawtinLifeSci Communications603-714-2638[email protected] SOURCE Nektar Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News